# Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

> **NCT04972227** · PHASE1 · COMPLETED · sponsor: **Tisento Therapeutics** · enrollment: 48 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** CY6463
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04972227
- **Lead sponsor:** Tisento Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-04-18
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04972227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04972227, "Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04972227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*